502 related articles for article (PubMed ID: 17822493)
21. An alternate-day corticosteroid regimen for pemphigus vulgaris. A 13-year prospective study.
Chaidemenos GCh; Mourellou O; Koussidou T; Tsatsou F
J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1386-91. PubMed ID: 17958846
[TBL] [Abstract][Full Text] [Related]
22. Pemphigus: analysis of 1209 cases.
Chams-Davatchi C; Valikhani M; Daneshpazhooh M; Esmaili N; Balighi K; Hallaji Z; Barzegari M; Akhiani M; Ghodsi Z; Mortazavi H; Naraghi Z
Int J Dermatol; 2005 Jun; 44(6):470-6. PubMed ID: 15941433
[TBL] [Abstract][Full Text] [Related]
23. A 6-year treatment experience for pemphigus: retrospective study of 69 Chinese patients.
Bai YX; Zhang LM; Xiao T; Chen HD
Dermatol Ther; 2016; 29(2):84-7. PubMed ID: 27060935
[TBL] [Abstract][Full Text] [Related]
24. The course and prognosis of pemphigus in 47 Tunisian patients.
Khaled A; Taazayet SB; Ben Alaya N; Souissi A; Zeglaoui F; Kaffel N; Kharfi M; Zermani R; Fazaa B
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):81-5. PubMed ID: 22145661
[TBL] [Abstract][Full Text] [Related]
25. Childhood pemphigus vulgaris: five cases in 16 years.
Yazganoğlu KD; Baykal C; Küçükoğlu R
J Dermatol; 2006 Dec; 33(12):846-9. PubMed ID: 17169087
[TBL] [Abstract][Full Text] [Related]
26. Sensitivity of indirect immunofluorescence and ELISA in detecting intercellular antibodies in endemic pemphigus foliaceus (Fogo Selvagem).
Cunha PR; Bystryn JC; Medeiros EP; de Oliveira JR
Int J Dermatol; 2006 Aug; 45(8):914-8. PubMed ID: 16911373
[TBL] [Abstract][Full Text] [Related]
27. The impact of stratifying initial dose of corticosteroids by severity of pemphigus vulgaris on long-term disease severity.
Lyakhovitsky A; Baum S; Scope A; Amichai B; Barzilai A; Rimer J; Trau H
Int J Dermatol; 2011 Aug; 50(8):1014-9. PubMed ID: 21781080
[TBL] [Abstract][Full Text] [Related]
28. Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab.
Pfütze M; Eming R; Kneisel A; Kuhlmann U; Hoyer J; Hertl M
Dermatology; 2009; 218(3):237-45. PubMed ID: 19088461
[TBL] [Abstract][Full Text] [Related]
29. [Statistical observations of pemphigus at the Nara University Hospital from 1975 to 1989].
Nakatani C; Matsuoka A; Muramatsu T; Miyagawa S; Sakamoto K; Shirai T
Nihon Hifuka Gakkai Zasshi; 1991 Jul; 101(8):831-5. PubMed ID: 1942587
[TBL] [Abstract][Full Text] [Related]
30. Pemphigus in the Mediterranean region of Turkey: a study of 148 cases.
Uzun S; Durdu M; Akman A; Gunasti S; Uslular C; Memisoglu HR; Alpsoy E
Int J Dermatol; 2006 May; 45(5):523-8. PubMed ID: 16700784
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of pemphigus vulgaris by azathioprine and low doses of prednisone (Lever scheme)].
Benoit Corven C; Carvalho P; Prost C; Verret JL; Saiag P; Noblesse I; Bedane C; Chosidow O; Young P; Roujeau JC; Joly P
Ann Dermatol Venereol; 2003 Jan; 130(1 Pt 1):13-5. PubMed ID: 12605150
[TBL] [Abstract][Full Text] [Related]
32. Outcome of pemphigus vulgaris.
Kavusi S; Daneshpazhooh M; Farahani F; Abedini R; Lajevardi V; Chams-Davatchi C
J Eur Acad Dermatol Venereol; 2008 May; 22(5):580-4. PubMed ID: 18194237
[TBL] [Abstract][Full Text] [Related]
33. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.
Ahmed AR
J Am Acad Dermatol; 2001 Nov; 45(5):679-90. PubMed ID: 11606916
[TBL] [Abstract][Full Text] [Related]
34. A clinical study of patients with pemphigus vulgaris and pemphigus foliaceous: an 11-year retrospective study (1996-2006).
Ishii N; Maeyama Y; Karashima T; Nakama T; Kusuhara M; Yasumoto S; Hashimoto T
Clin Exp Dermatol; 2008 Aug; 33(5):641-3. PubMed ID: 18627388
[TBL] [Abstract][Full Text] [Related]
35. Disease progression and response to therapy in pemphigus based on a registry.
Pieper J; Pollmann R; Eming R; Greene B; Hahmann M; Hertl M
J Dtsch Dermatol Ges; 2022 Apr; 20(4):461-467. PubMed ID: 35446493
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous pemphigus vulgaris with skin features similar to the classic mucocutaneous type: a case report and review of the literature.
Shinkuma S; Nishie W; Shibaki A; Sawamura D; Ito K; Tsuji-Abe Y; Natsuga K; Chan PT; Amagai M; Shimizu H
Clin Exp Dermatol; 2008 Nov; 33(6):724-8. PubMed ID: 18627395
[TBL] [Abstract][Full Text] [Related]
37. Evaluating efficacy of plasmapheresis for patients with pemphigus using desmoglein enzyme-linked immunosorbent assay.
Nagasaka T; Fujii Y; Ishida A; Handa M; Tanikawa A; Amagai M; Nishikawa T
Br J Dermatol; 2008 Apr; 158(4):685-90. PubMed ID: 18241273
[TBL] [Abstract][Full Text] [Related]
38. Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy.
Keskin DB; Stern JN; Fridkis-Hareli M; Razzaque Ahmed A
Cytokine; 2008 Mar; 41(3):315-21. PubMed ID: 18289869
[TBL] [Abstract][Full Text] [Related]
39. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris.
Engineer L; Bhol KC; Ahmed AR
J Am Acad Dermatol; 2000 Dec; 43(6):1049-57. PubMed ID: 11100022
[TBL] [Abstract][Full Text] [Related]
40. Pemphigus vulgaris localized to the nose and cheeks.
Baykal C; Azizlerli G; Thoma-Uszynski S; Hertl M
J Am Acad Dermatol; 2002 Dec; 47(6):875-80. PubMed ID: 12451372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
